ASCO 2017 – Multiple Myeloma

MMY1001 is an open-label phase 1b study of daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed patients with multiple myeloma.

Open-Label, Single-Arm Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone, and Elotuzumab in Newly Diagnosed MM

The combination of elotuzumab, bortezomib, lenalidomide, and dexamethasone is effective in patients with newly diagnosed multiple myeloma (MM).

A Phase 1b Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

A phase 1b study showed that isatuximab is clinically active in patients with relapsed/refractory multiple myeloma.

Phase 1/2 Dose Expansion of a Trial Investigating Bendamustine and Pomalidomide with Dexamethasone in Patients with RRMM

The combination of bendamustine and pomalidomide with dexamethasone shows promise in patients with relapsed/refractory multiple myeloma (RRMM).

Doxorubicin Hydrochloride, Lenalidomide, and Dexamethasone versus Bortezomib, Lenalidomide, and Dexamethasone Prior to Scheduled Stem-Cell Transplant in Newly Diagnosed Myeloma

The DSMM XIV study highlights the efficacy of bortezomib versus doxorubicin in combination with lenalidomide and dexamethasone prior to stem-cell transplant in patients with newly diagnosed multiple myeloma.

Lenalidomide Induction and Maintenance Therapy for Transplant-Eligible Myeloma Patients: Results of the Myeloma XI Study

The Myeloma XI Study analyzed lenalidomide induction and maintenance therapy in transplant-eligible patients with myeloma.

Impact of t(11;14) on Outcomes in African American and Non–African American Patients with NDMM: Connect MM Registry

Data from the Connect MM Registry show poor survival outcomes in African American patients with newly diagnosed multiple myeloma (NDMM) and t(11;14) mutation.

Pembrolizumab plus Lenalidomide and Low-Dose Dexamethasone for RRMM: Efficacy and Biomarker Analyses

Results from the KEYNOTE-023 trial show that the combination of pembrolizumab plus lenalidomide and low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma (RRMM).

First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T-Cell Therapy for RRMM: Updated Results

Chimeric antigen receptor (CAR) T-cell therapy with bb2121 shows a promising new treatment paradigm in patients with relapsed/refractory multiple myeloma (RRMM).

Pomalidomide + Low-Dose Dexamethasone after Lenalidomide-Based Second-Line Treatment in Patients with RRMM: Analysis of Progression-Free Survival by Level of Disease Control

Pomalidomide plus low-dose dexamethasone used as third-line therapy improves survival outcomes in patients with relapsed/refractory multiple myeloma (RRMM).